A phase 1 study of PMN-310 for Alzheimer's disease

Trial Profile

A phase 1 study of PMN-310 for Alzheimer's disease

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs PMN 310 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jun 2018 According to a ProMIS Neurosciences media release, the molecule PMN310 is anticipated to enter phase 1 trial in second half of 2019.
    • 13 Sep 2017 According to a ProMIS Neurosciences media release, the molecule PMN310 is on track for initiation of this trial in 2019.
    • 05 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top